http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 21 May 2026 08:45:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/MIMEDX+to+Participate+in+Craig-Hallum+23rd+Annual+Institutional+Investor+Conference/26532080.html <p align="left">MARIETTA, Ga., May 21, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the <strong>Craig-Hallum 23</strong>^{<strong>rd</strong>}<strong> Annual Institutional Investor Conference </strong>on Thursday, May 28, 2026 in Minneapolis, MN. Investors interested in meeting with senior management may contact their Craig-Hallum representative.</p> <p align="left"><strong>About MIMEDX</strong><br />MIMEDX is a pioneer and leader focused on helping humans heal. With more than a decade and a half of helping clinicians manage chronic and other hard-to-heal wounds, MIMEDX provides a leading portfolio of products for applications in the http://www.streetinsider.com/Press+Releases/MIMEDX+to+Participate+in+Craig-Hallum+23rd+Annual+Institutional+Investor+Conference/26532080.html Thu, 21 May 2026 08:45:00 -0400 MDXG http://www.streetinsider.com/Globe+Newswire/MIMEDX+to+Participate+in+Craig-Hallum+23rd+Annual+Institutional+Investor+Conference/26532080.html <p align="left">MARIETTA, Ga., May 21, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the <strong>Craig-Hallum 23</strong>^{<strong>rd</strong>}<strong> Annual Institutional Investor Conference </strong>on Thursday, May 28, 2026 in Minneapolis, MN. Investors interested in meeting with senior management may contact their Craig-Hallum representative.</p> <p align="left"><strong>About MIMEDX</strong><br />MIMEDX is a pioneer and leader focused on helping humans heal. With more than a decade and a half of helping clinicians manage chronic and other hard-to-heal wounds, MIMEDX provides a leading portfolio of products for applications in the http://www.streetinsider.com/Globe+Newswire/MIMEDX+to+Participate+in+Craig-Hallum+23rd+Annual+Institutional+Investor+Conference/26532080.html Thu, 21 May 2026 08:45:00 -0400 MDXG http://www.streetinsider.com/Corporate+News/MIMEDX+launches+G4Derm+Plus+wound+care+product+with+nationwide+sales/26457997.html <p>MiMedx Group Inc. (NASDAQ: MDXG) announced the commercial launch of G4Derm Plus, a flowable biomimetic matrix for wound management. The company reported that initial sales have been delivered to customers nationwide.</p><p>MIMEDX acquired exclusive distribution rights for G4Derm Plus in the United States. The product utilizes self-assembling peptide technology to form a three-dimensional scaffold that mimics native extracellular matrix.</p><p>G4Derm Plus is designed to manage complex wounds by supporting tissue regrowth and serving as an antibacterial barrier. The product received 510(k) clearance from the Food and Drug Administration.</p><p>"This launch showcases our efforts to leverage our sizable commercial reach to expand solutions available http://www.streetinsider.com/Corporate+News/MIMEDX+launches+G4Derm+Plus+wound+care+product+with+nationwide+sales/26457997.html Fri, 08 May 2026 08:00:38 -0400 MDXG http://www.streetinsider.com/FDA/MIMEDX+launches+G4Derm+Plus+wound+care+product+with+nationwide+sales/26457997.html <p>MiMedx Group Inc. (NASDAQ: MDXG) announced the commercial launch of G4Derm Plus, a flowable biomimetic matrix for wound management. The company reported that initial sales have been delivered to customers nationwide.</p><p>MIMEDX acquired exclusive distribution rights for G4Derm Plus in the United States. The product utilizes self-assembling peptide technology to form a three-dimensional scaffold that mimics native extracellular matrix.</p><p>G4Derm Plus is designed to manage complex wounds by supporting tissue regrowth and serving as an antibacterial barrier. The product received 510(k) clearance from the Food and Drug Administration.</p><p>"This launch showcases our efforts to leverage our sizable commercial reach to expand solutions available http://www.streetinsider.com/FDA/MIMEDX+launches+G4Derm+Plus+wound+care+product+with+nationwide+sales/26457997.html Fri, 08 May 2026 08:00:38 -0400 MDXG http://www.streetinsider.com/Press+Releases/MIMEDX+Announces+Launch+of+G4Derm%C2%AE+Plus/26457961.html <p align="center"><em>Flowable Biomimetic Matrix Adds Self-Assembling Peptide Technology to Company’s Portfolio</em></p> <p align="center"><em>G4Derm Plus Added to Premier and Vizient GPO Agreements</em></p> <p>MARIETTA, Ga., May 08, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the commercial launch of G4Derm Plus, with initial sales of the product already delivered to customers nationwide. MIMEDX recently acquired exclusive distribution rights for G4Derm Plus in the United States, adding the innovative peptide matrix to its broadening portfolio of solutions for Surgical markets.</p> <p>“This launch showcases our efforts to leverage our sizable commercial reach http://www.streetinsider.com/Press+Releases/MIMEDX+Announces+Launch+of+G4Derm%C2%AE+Plus/26457961.html Fri, 08 May 2026 08:00:00 -0400 A.34824225 MDXG O.06574964 O.26772469 http://www.streetinsider.com/Press+Releases/MIMEDX+Announces+Launch+of+G4Derm%C2%AE+Plus/26457961.html <p align="center"><em>Flowable Biomimetic Matrix Adds Self-Assembling Peptide Technology to Company’s Portfolio</em></p> <p align="center"><em>G4Derm Plus Added to Premier and Vizient GPO Agreements</em></p> <p>MARIETTA, Ga., May 08, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the commercial launch of G4Derm Plus, with initial sales of the product already delivered to customers nationwide. MIMEDX recently acquired exclusive distribution rights for G4Derm Plus in the United States, adding the innovative peptide matrix to its broadening portfolio of solutions for Surgical markets.</p> <p>“This launch showcases our efforts to leverage our sizable commercial reach http://www.streetinsider.com/Press+Releases/MIMEDX+Announces+Launch+of+G4Derm%C2%AE+Plus/26457961.html Fri, 08 May 2026 08:00:00 -0400 A.34824225 MDXG O.06574964 O.26772469 http://www.streetinsider.com/Press+Releases/MIMEDX+Announces+Launch+of+G4Derm%C2%AE+Plus/26457961.html <p align="center"><em>Flowable Biomimetic Matrix Adds Self-Assembling Peptide Technology to Company’s Portfolio</em></p> <p align="center"><em>G4Derm Plus Added to Premier and Vizient GPO Agreements</em></p> <p>MARIETTA, Ga., May 08, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the commercial launch of G4Derm Plus, with initial sales of the product already delivered to customers nationwide. MIMEDX recently acquired exclusive distribution rights for G4Derm Plus in the United States, adding the innovative peptide matrix to its broadening portfolio of solutions for Surgical markets.</p> <p>“This launch showcases our efforts to leverage our sizable commercial reach http://www.streetinsider.com/Press+Releases/MIMEDX+Announces+Launch+of+G4Derm%C2%AE+Plus/26457961.html Fri, 08 May 2026 08:00:00 -0400 A.34824225 MDXG O.06574964 O.26772469 http://www.streetinsider.com/Press+Releases/MIMEDX+Announces+Launch+of+G4Derm%C2%AE+Plus/26457961.html <p align="center"><em>Flowable Biomimetic Matrix Adds Self-Assembling Peptide Technology to Company’s Portfolio</em></p> <p align="center"><em>G4Derm Plus Added to Premier and Vizient GPO Agreements</em></p> <p>MARIETTA, Ga., May 08, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the commercial launch of G4Derm Plus, with initial sales of the product already delivered to customers nationwide. MIMEDX recently acquired exclusive distribution rights for G4Derm Plus in the United States, adding the innovative peptide matrix to its broadening portfolio of solutions for Surgical markets.</p> <p>“This launch showcases our efforts to leverage our sizable commercial reach http://www.streetinsider.com/Press+Releases/MIMEDX+Announces+Launch+of+G4Derm%C2%AE+Plus/26457961.html Fri, 08 May 2026 08:00:00 -0400 A.34824225 MDXG O.06574964 O.26772469 http://www.streetinsider.com/Globe+Newswire/MIMEDX+Announces+Launch+of+G4Derm%C2%AE+Plus/26457961.html <p align="center"><em>Flowable Biomimetic Matrix Adds Self-Assembling Peptide Technology to Company’s Portfolio</em></p> <p align="center"><em>G4Derm Plus Added to Premier and Vizient GPO Agreements</em></p> <p>MARIETTA, Ga., May 08, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the commercial launch of G4Derm Plus, with initial sales of the product already delivered to customers nationwide. MIMEDX recently acquired exclusive distribution rights for G4Derm Plus in the United States, adding the innovative peptide matrix to its broadening portfolio of solutions for Surgical markets.</p> <p>“This launch showcases our efforts to leverage our sizable commercial reach http://www.streetinsider.com/Globe+Newswire/MIMEDX+Announces+Launch+of+G4Derm%C2%AE+Plus/26457961.html Fri, 08 May 2026 08:00:00 -0400 A.34824225 MDXG O.06574964 O.26772469 http://www.streetinsider.com/Globe+Newswire/MIMEDX+Announces+Launch+of+G4Derm%C2%AE+Plus/26457961.html <p align="center"><em>Flowable Biomimetic Matrix Adds Self-Assembling Peptide Technology to Company’s Portfolio</em></p> <p align="center"><em>G4Derm Plus Added to Premier and Vizient GPO Agreements</em></p> <p>MARIETTA, Ga., May 08, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the commercial launch of G4Derm Plus, with initial sales of the product already delivered to customers nationwide. MIMEDX recently acquired exclusive distribution rights for G4Derm Plus in the United States, adding the innovative peptide matrix to its broadening portfolio of solutions for Surgical markets.</p> <p>“This launch showcases our efforts to leverage our sizable commercial reach http://www.streetinsider.com/Globe+Newswire/MIMEDX+Announces+Launch+of+G4Derm%C2%AE+Plus/26457961.html Fri, 08 May 2026 08:00:00 -0400 A.34824225 MDXG O.06574964 O.26772469 http://www.streetinsider.com/Globe+Newswire/MIMEDX+Announces+Launch+of+G4Derm%C2%AE+Plus/26457961.html <p align="center"><em>Flowable Biomimetic Matrix Adds Self-Assembling Peptide Technology to Company’s Portfolio</em></p> <p align="center"><em>G4Derm Plus Added to Premier and Vizient GPO Agreements</em></p> <p>MARIETTA, Ga., May 08, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the commercial launch of G4Derm Plus, with initial sales of the product already delivered to customers nationwide. MIMEDX recently acquired exclusive distribution rights for G4Derm Plus in the United States, adding the innovative peptide matrix to its broadening portfolio of solutions for Surgical markets.</p> <p>“This launch showcases our efforts to leverage our sizable commercial reach http://www.streetinsider.com/Globe+Newswire/MIMEDX+Announces+Launch+of+G4Derm%C2%AE+Plus/26457961.html Fri, 08 May 2026 08:00:00 -0400 A.34824225 MDXG O.06574964 O.26772469 http://www.streetinsider.com/Globe+Newswire/MIMEDX+Announces+Launch+of+G4Derm%C2%AE+Plus/26457961.html <p align="center"><em>Flowable Biomimetic Matrix Adds Self-Assembling Peptide Technology to Company’s Portfolio</em></p> <p align="center"><em>G4Derm Plus Added to Premier and Vizient GPO Agreements</em></p> <p>MARIETTA, Ga., May 08, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the commercial launch of G4Derm Plus, with initial sales of the product already delivered to customers nationwide. MIMEDX recently acquired exclusive distribution rights for G4Derm Plus in the United States, adding the innovative peptide matrix to its broadening portfolio of solutions for Surgical markets.</p> <p>“This launch showcases our efforts to leverage our sizable commercial reach http://www.streetinsider.com/Globe+Newswire/MIMEDX+Announces+Launch+of+G4Derm%C2%AE+Plus/26457961.html Fri, 08 May 2026 08:00:00 -0400 A.34824225 MDXG O.06574964 O.26772469 http://www.streetinsider.com/Press+Releases/TELA+Bio+Announces+Strategic+Board+Refreshment+with+Four+Highly+Experienced+Commerical+Leaders+to+Accelerate+Growth+and+Drive+Path+to+Profitability%3B+The+Company+Also+Reports+Preliminary+First+Quarter+/26409359.html <p align="left">MALVERN, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced a comprehensive board refreshment plan designed to support the Company’s next phase of commercial growth and operational excellence.</p> <p>In a unanimous decision by the current seven-member Board of Directors, four respected directors have agreed to step down following the Company’s 2026 Annual Meeting of Stockholders on June 9, 2026 (the “2026 Annual Meeting”), to make room for four new highly accomplished executives with deep expertise in medtech commercialization, financial http://www.streetinsider.com/Press+Releases/TELA+Bio+Announces+Strategic+Board+Refreshment+with+Four+Highly+Experienced+Commerical+Leaders+to+Accelerate+Growth+and+Drive+Path+to+Profitability%3B+The+Company+Also+Reports+Preliminary+First+Quarter+/26409359.html Thu, 30 Apr 2026 16:43:00 -0400 A.03854270 A.06372891 A.07275829 A.08164575 A.08377063 A.08423586 A.11399736 A.11608963 A.14067231 A.16852497 A.20009571 A.22499170 A.32289834 A.33634610 A.33902756 A.35454529 A.50203584 ANIK AXGN BVS ELUT MDXG O.00026248 O.00028494 O.00092737 O.00173818 O.01163638 O.02760651 O.04701423 O.04848105 O.05010326 O.05016941 O.06574964 O.07126568 O.08234601 O.15817314 O.18720149 O.19903583 O.20976440 O.24070172 O.25928637 O.29996804 O.30836334 O.31701438 O.59913331 TELA http://www.streetinsider.com/Press+Releases/TELA+Bio+Announces+Strategic+Board+Refreshment+with+Four+Highly+Experienced+Commerical+Leaders+to+Accelerate+Growth+and+Drive+Path+to+Profitability%3B+The+Company+Also+Reports+Preliminary+First+Quarter+/26409359.html <p align="left">MALVERN, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced a comprehensive board refreshment plan designed to support the Company’s next phase of commercial growth and operational excellence.</p> <p>In a unanimous decision by the current seven-member Board of Directors, four respected directors have agreed to step down following the Company’s 2026 Annual Meeting of Stockholders on June 9, 2026 (the “2026 Annual Meeting”), to make room for four new highly accomplished executives with deep expertise in medtech commercialization, financial http://www.streetinsider.com/Press+Releases/TELA+Bio+Announces+Strategic+Board+Refreshment+with+Four+Highly+Experienced+Commerical+Leaders+to+Accelerate+Growth+and+Drive+Path+to+Profitability%3B+The+Company+Also+Reports+Preliminary+First+Quarter+/26409359.html Thu, 30 Apr 2026 16:43:00 -0400 A.03854270 A.06372891 A.07275829 A.08164575 A.08377063 A.08423586 A.11399736 A.11608963 A.14067231 A.16852497 A.20009571 A.22499170 A.32289834 A.33634610 A.33902756 A.35454529 A.50203584 ANIK AXGN BVS ELUT MDXG O.00026248 O.00028494 O.00092737 O.00173818 O.01163638 O.02760651 O.04701423 O.04848105 O.05010326 O.05016941 O.06574964 O.07126568 O.08234601 O.15817314 O.18720149 O.19903583 O.20976440 O.24070172 O.25928637 O.29996804 O.30836334 O.31701438 O.59913331 TELA http://www.streetinsider.com/Press+Releases/TELA+Bio+Announces+Strategic+Board+Refreshment+with+Four+Highly+Experienced+Commerical+Leaders+to+Accelerate+Growth+and+Drive+Path+to+Profitability%3B+The+Company+Also+Reports+Preliminary+First+Quarter+/26409359.html <p align="left">MALVERN, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced a comprehensive board refreshment plan designed to support the Company’s next phase of commercial growth and operational excellence.</p> <p>In a unanimous decision by the current seven-member Board of Directors, four respected directors have agreed to step down following the Company’s 2026 Annual Meeting of Stockholders on June 9, 2026 (the “2026 Annual Meeting”), to make room for four new highly accomplished executives with deep expertise in medtech commercialization, financial http://www.streetinsider.com/Press+Releases/TELA+Bio+Announces+Strategic+Board+Refreshment+with+Four+Highly+Experienced+Commerical+Leaders+to+Accelerate+Growth+and+Drive+Path+to+Profitability%3B+The+Company+Also+Reports+Preliminary+First+Quarter+/26409359.html Thu, 30 Apr 2026 16:43:00 -0400 A.03854270 A.06372891 A.07275829 A.08164575 A.08377063 A.08423586 A.11399736 A.11608963 A.14067231 A.16852497 A.20009571 A.22499170 A.32289834 A.33634610 A.33902756 A.35454529 A.50203584 ANIK AXGN BVS ELUT MDXG O.00026248 O.00028494 O.00092737 O.00173818 O.01163638 O.02760651 O.04701423 O.04848105 O.05010326 O.05016941 O.06574964 O.07126568 O.08234601 O.15817314 O.18720149 O.19903583 O.20976440 O.24070172 O.25928637 O.29996804 O.30836334 O.31701438 O.59913331 TELA http://www.streetinsider.com/Press+Releases/TELA+Bio+Announces+Strategic+Board+Refreshment+with+Four+Highly+Experienced+Commerical+Leaders+to+Accelerate+Growth+and+Drive+Path+to+Profitability%3B+The+Company+Also+Reports+Preliminary+First+Quarter+/26409359.html <p align="left">MALVERN, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced a comprehensive board refreshment plan designed to support the Company’s next phase of commercial growth and operational excellence.</p> <p>In a unanimous decision by the current seven-member Board of Directors, four respected directors have agreed to step down following the Company’s 2026 Annual Meeting of Stockholders on June 9, 2026 (the “2026 Annual Meeting”), to make room for four new highly accomplished executives with deep expertise in medtech commercialization, financial http://www.streetinsider.com/Press+Releases/TELA+Bio+Announces+Strategic+Board+Refreshment+with+Four+Highly+Experienced+Commerical+Leaders+to+Accelerate+Growth+and+Drive+Path+to+Profitability%3B+The+Company+Also+Reports+Preliminary+First+Quarter+/26409359.html Thu, 30 Apr 2026 16:43:00 -0400 A.03854270 A.06372891 A.07275829 A.08164575 A.08377063 A.08423586 A.11399736 A.11608963 A.14067231 A.16852497 A.20009571 A.22499170 A.32289834 A.33634610 A.33902756 A.35454529 A.50203584 ANIK AXGN BVS ELUT MDXG O.00026248 O.00028494 O.00092737 O.00173818 O.01163638 O.02760651 O.04701423 O.04848105 O.05010326 O.05016941 O.06574964 O.07126568 O.08234601 O.15817314 O.18720149 O.19903583 O.20976440 O.24070172 O.25928637 O.29996804 O.30836334 O.31701438 O.59913331 TELA http://www.streetinsider.com/Press+Releases/TELA+Bio+Announces+Strategic+Board+Refreshment+with+Four+Highly+Experienced+Commerical+Leaders+to+Accelerate+Growth+and+Drive+Path+to+Profitability%3B+The+Company+Also+Reports+Preliminary+First+Quarter+/26409359.html <p align="left">MALVERN, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced a comprehensive board refreshment plan designed to support the Company’s next phase of commercial growth and operational excellence.</p> <p>In a unanimous decision by the current seven-member Board of Directors, four respected directors have agreed to step down following the Company’s 2026 Annual Meeting of Stockholders on June 9, 2026 (the “2026 Annual Meeting”), to make room for four new highly accomplished executives with deep expertise in medtech commercialization, financial http://www.streetinsider.com/Press+Releases/TELA+Bio+Announces+Strategic+Board+Refreshment+with+Four+Highly+Experienced+Commerical+Leaders+to+Accelerate+Growth+and+Drive+Path+to+Profitability%3B+The+Company+Also+Reports+Preliminary+First+Quarter+/26409359.html Thu, 30 Apr 2026 16:43:00 -0400 A.03854270 A.06372891 A.07275829 A.08164575 A.08377063 A.08423586 A.11399736 A.11608963 A.14067231 A.16852497 A.20009571 A.22499170 A.32289834 A.33634610 A.33902756 A.35454529 A.50203584 ANIK AXGN BVS ELUT MDXG O.00026248 O.00028494 O.00092737 O.00173818 O.01163638 O.02760651 O.04701423 O.04848105 O.05010326 O.05016941 O.06574964 O.07126568 O.08234601 O.15817314 O.18720149 O.19903583 O.20976440 O.24070172 O.25928637 O.29996804 O.30836334 O.31701438 O.59913331 TELA http://www.streetinsider.com/Press+Releases/TELA+Bio+Announces+Strategic+Board+Refreshment+with+Four+Highly+Experienced+Commerical+Leaders+to+Accelerate+Growth+and+Drive+Path+to+Profitability%3B+The+Company+Also+Reports+Preliminary+First+Quarter+/26409359.html <p align="left">MALVERN, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced a comprehensive board refreshment plan designed to support the Company’s next phase of commercial growth and operational excellence.</p> <p>In a unanimous decision by the current seven-member Board of Directors, four respected directors have agreed to step down following the Company’s 2026 Annual Meeting of Stockholders on June 9, 2026 (the “2026 Annual Meeting”), to make room for four new highly accomplished executives with deep expertise in medtech commercialization, financial http://www.streetinsider.com/Press+Releases/TELA+Bio+Announces+Strategic+Board+Refreshment+with+Four+Highly+Experienced+Commerical+Leaders+to+Accelerate+Growth+and+Drive+Path+to+Profitability%3B+The+Company+Also+Reports+Preliminary+First+Quarter+/26409359.html Thu, 30 Apr 2026 16:43:00 -0400 A.03854270 A.06372891 A.07275829 A.08164575 A.08377063 A.08423586 A.11399736 A.11608963 A.14067231 A.16852497 A.20009571 A.22499170 A.32289834 A.33634610 A.33902756 A.35454529 A.50203584 ANIK AXGN BVS ELUT MDXG O.00026248 O.00028494 O.00092737 O.00173818 O.01163638 O.02760651 O.04701423 O.04848105 O.05010326 O.05016941 O.06574964 O.07126568 O.08234601 O.15817314 O.18720149 O.19903583 O.20976440 O.24070172 O.25928637 O.29996804 O.30836334 O.31701438 O.59913331 TELA http://www.streetinsider.com/Press+Releases/TELA+Bio+Announces+Strategic+Board+Refreshment+with+Four+Highly+Experienced+Commerical+Leaders+to+Accelerate+Growth+and+Drive+Path+to+Profitability%3B+The+Company+Also+Reports+Preliminary+First+Quarter+/26409359.html <p align="left">MALVERN, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced a comprehensive board refreshment plan designed to support the Company’s next phase of commercial growth and operational excellence.</p> <p>In a unanimous decision by the current seven-member Board of Directors, four respected directors have agreed to step down following the Company’s 2026 Annual Meeting of Stockholders on June 9, 2026 (the “2026 Annual Meeting”), to make room for four new highly accomplished executives with deep expertise in medtech commercialization, financial http://www.streetinsider.com/Press+Releases/TELA+Bio+Announces+Strategic+Board+Refreshment+with+Four+Highly+Experienced+Commerical+Leaders+to+Accelerate+Growth+and+Drive+Path+to+Profitability%3B+The+Company+Also+Reports+Preliminary+First+Quarter+/26409359.html Thu, 30 Apr 2026 16:43:00 -0400 A.03854270 A.06372891 A.07275829 A.08164575 A.08377063 A.08423586 A.11399736 A.11608963 A.14067231 A.16852497 A.20009571 A.22499170 A.32289834 A.33634610 A.33902756 A.35454529 A.50203584 ANIK AXGN BVS ELUT MDXG O.00026248 O.00028494 O.00092737 O.00173818 O.01163638 O.02760651 O.04701423 O.04848105 O.05010326 O.05016941 O.06574964 O.07126568 O.08234601 O.15817314 O.18720149 O.19903583 O.20976440 O.24070172 O.25928637 O.29996804 O.30836334 O.31701438 O.59913331 TELA http://www.streetinsider.com/Press+Releases/TELA+Bio+Announces+Strategic+Board+Refreshment+with+Four+Highly+Experienced+Commerical+Leaders+to+Accelerate+Growth+and+Drive+Path+to+Profitability%3B+The+Company+Also+Reports+Preliminary+First+Quarter+/26409359.html <p align="left">MALVERN, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced a comprehensive board refreshment plan designed to support the Company’s next phase of commercial growth and operational excellence.</p> <p>In a unanimous decision by the current seven-member Board of Directors, four respected directors have agreed to step down following the Company’s 2026 Annual Meeting of Stockholders on June 9, 2026 (the “2026 Annual Meeting”), to make room for four new highly accomplished executives with deep expertise in medtech commercialization, financial http://www.streetinsider.com/Press+Releases/TELA+Bio+Announces+Strategic+Board+Refreshment+with+Four+Highly+Experienced+Commerical+Leaders+to+Accelerate+Growth+and+Drive+Path+to+Profitability%3B+The+Company+Also+Reports+Preliminary+First+Quarter+/26409359.html Thu, 30 Apr 2026 16:43:00 -0400 A.03854270 A.06372891 A.07275829 A.08164575 A.08377063 A.08423586 A.11399736 A.11608963 A.14067231 A.16852497 A.20009571 A.22499170 A.32289834 A.33634610 A.33902756 A.35454529 A.50203584 ANIK AXGN BVS ELUT MDXG O.00026248 O.00028494 O.00092737 O.00173818 O.01163638 O.02760651 O.04701423 O.04848105 O.05010326 O.05016941 O.06574964 O.07126568 O.08234601 O.15817314 O.18720149 O.19903583 O.20976440 O.24070172 O.25928637 O.29996804 O.30836334 O.31701438 O.59913331 TELA http://www.streetinsider.com/Press+Releases/TELA+Bio+Announces+Strategic+Board+Refreshment+with+Four+Highly+Experienced+Commerical+Leaders+to+Accelerate+Growth+and+Drive+Path+to+Profitability%3B+The+Company+Also+Reports+Preliminary+First+Quarter+/26409359.html <p align="left">MALVERN, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced a comprehensive board refreshment plan designed to support the Company’s next phase of commercial growth and operational excellence.</p> <p>In a unanimous decision by the current seven-member Board of Directors, four respected directors have agreed to step down following the Company’s 2026 Annual Meeting of Stockholders on June 9, 2026 (the “2026 Annual Meeting”), to make room for four new highly accomplished executives with deep expertise in medtech commercialization, financial http://www.streetinsider.com/Press+Releases/TELA+Bio+Announces+Strategic+Board+Refreshment+with+Four+Highly+Experienced+Commerical+Leaders+to+Accelerate+Growth+and+Drive+Path+to+Profitability%3B+The+Company+Also+Reports+Preliminary+First+Quarter+/26409359.html Thu, 30 Apr 2026 16:43:00 -0400 A.03854270 A.06372891 A.07275829 A.08164575 A.08377063 A.08423586 A.11399736 A.11608963 A.14067231 A.16852497 A.20009571 A.22499170 A.32289834 A.33634610 A.33902756 A.35454529 A.50203584 ANIK AXGN BVS ELUT MDXG O.00026248 O.00028494 O.00092737 O.00173818 O.01163638 O.02760651 O.04701423 O.04848105 O.05010326 O.05016941 O.06574964 O.07126568 O.08234601 O.15817314 O.18720149 O.19903583 O.20976440 O.24070172 O.25928637 O.29996804 O.30836334 O.31701438 O.59913331 TELA http://www.streetinsider.com/Press+Releases/TELA+Bio+Announces+Strategic+Board+Refreshment+with+Four+Highly+Experienced+Commerical+Leaders+to+Accelerate+Growth+and+Drive+Path+to+Profitability%3B+The+Company+Also+Reports+Preliminary+First+Quarter+/26409359.html <p align="left">MALVERN, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced a comprehensive board refreshment plan designed to support the Company’s next phase of commercial growth and operational excellence.</p> <p>In a unanimous decision by the current seven-member Board of Directors, four respected directors have agreed to step down following the Company’s 2026 Annual Meeting of Stockholders on June 9, 2026 (the “2026 Annual Meeting”), to make room for four new highly accomplished executives with deep expertise in medtech commercialization, financial http://www.streetinsider.com/Press+Releases/TELA+Bio+Announces+Strategic+Board+Refreshment+with+Four+Highly+Experienced+Commerical+Leaders+to+Accelerate+Growth+and+Drive+Path+to+Profitability%3B+The+Company+Also+Reports+Preliminary+First+Quarter+/26409359.html Thu, 30 Apr 2026 16:43:00 -0400 A.03854270 A.06372891 A.07275829 A.08164575 A.08377063 A.08423586 A.11399736 A.11608963 A.14067231 A.16852497 A.20009571 A.22499170 A.32289834 A.33634610 A.33902756 A.35454529 A.50203584 ANIK AXGN BVS ELUT MDXG O.00026248 O.00028494 O.00092737 O.00173818 O.01163638 O.02760651 O.04701423 O.04848105 O.05010326 O.05016941 O.06574964 O.07126568 O.08234601 O.15817314 O.18720149 O.19903583 O.20976440 O.24070172 O.25928637 O.29996804 O.30836334 O.31701438 O.59913331 TELA http://www.streetinsider.com/Press+Releases/TELA+Bio+Announces+Strategic+Board+Refreshment+with+Four+Highly+Experienced+Commerical+Leaders+to+Accelerate+Growth+and+Drive+Path+to+Profitability%3B+The+Company+Also+Reports+Preliminary+First+Quarter+/26409359.html <p align="left">MALVERN, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced a comprehensive board refreshment plan designed to support the Company’s next phase of commercial growth and operational excellence.</p> <p>In a unanimous decision by the current seven-member Board of Directors, four respected directors have agreed to step down following the Company’s 2026 Annual Meeting of Stockholders on June 9, 2026 (the “2026 Annual Meeting”), to make room for four new highly accomplished executives with deep expertise in medtech commercialization, financial http://www.streetinsider.com/Press+Releases/TELA+Bio+Announces+Strategic+Board+Refreshment+with+Four+Highly+Experienced+Commerical+Leaders+to+Accelerate+Growth+and+Drive+Path+to+Profitability%3B+The+Company+Also+Reports+Preliminary+First+Quarter+/26409359.html Thu, 30 Apr 2026 16:43:00 -0400 A.03854270 A.06372891 A.07275829 A.08164575 A.08377063 A.08423586 A.11399736 A.11608963 A.14067231 A.16852497 A.20009571 A.22499170 A.32289834 A.33634610 A.33902756 A.35454529 A.50203584 ANIK AXGN BVS ELUT MDXG O.00026248 O.00028494 O.00092737 O.00173818 O.01163638 O.02760651 O.04701423 O.04848105 O.05010326 O.05016941 O.06574964 O.07126568 O.08234601 O.15817314 O.18720149 O.19903583 O.20976440 O.24070172 O.25928637 O.29996804 O.30836334 O.31701438 O.59913331 TELA http://www.streetinsider.com/Press+Releases/TELA+Bio+Announces+Strategic+Board+Refreshment+with+Four+Highly+Experienced+Commerical+Leaders+to+Accelerate+Growth+and+Drive+Path+to+Profitability%3B+The+Company+Also+Reports+Preliminary+First+Quarter+/26409359.html <p align="left">MALVERN, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced a comprehensive board refreshment plan designed to support the Company’s next phase of commercial growth and operational excellence.</p> <p>In a unanimous decision by the current seven-member Board of Directors, four respected directors have agreed to step down following the Company’s 2026 Annual Meeting of Stockholders on June 9, 2026 (the “2026 Annual Meeting”), to make room for four new highly accomplished executives with deep expertise in medtech commercialization, financial http://www.streetinsider.com/Press+Releases/TELA+Bio+Announces+Strategic+Board+Refreshment+with+Four+Highly+Experienced+Commerical+Leaders+to+Accelerate+Growth+and+Drive+Path+to+Profitability%3B+The+Company+Also+Reports+Preliminary+First+Quarter+/26409359.html Thu, 30 Apr 2026 16:43:00 -0400 A.03854270 A.06372891 A.07275829 A.08164575 A.08377063 A.08423586 A.11399736 A.11608963 A.14067231 A.16852497 A.20009571 A.22499170 A.32289834 A.33634610 A.33902756 A.35454529 A.50203584 ANIK AXGN BVS ELUT MDXG O.00026248 O.00028494 O.00092737 O.00173818 O.01163638 O.02760651 O.04701423 O.04848105 O.05010326 O.05016941 O.06574964 O.07126568 O.08234601 O.15817314 O.18720149 O.19903583 O.20976440 O.24070172 O.25928637 O.29996804 O.30836334 O.31701438 O.59913331 TELA http://www.streetinsider.com/Press+Releases/TELA+Bio+Announces+Strategic+Board+Refreshment+with+Four+Highly+Experienced+Commerical+Leaders+to+Accelerate+Growth+and+Drive+Path+to+Profitability%3B+The+Company+Also+Reports+Preliminary+First+Quarter+/26409359.html <p align="left">MALVERN, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced a comprehensive board refreshment plan designed to support the Company’s next phase of commercial growth and operational excellence.</p> <p>In a unanimous decision by the current seven-member Board of Directors, four respected directors have agreed to step down following the Company’s 2026 Annual Meeting of Stockholders on June 9, 2026 (the “2026 Annual Meeting”), to make room for four new highly accomplished executives with deep expertise in medtech commercialization, financial http://www.streetinsider.com/Press+Releases/TELA+Bio+Announces+Strategic+Board+Refreshment+with+Four+Highly+Experienced+Commerical+Leaders+to+Accelerate+Growth+and+Drive+Path+to+Profitability%3B+The+Company+Also+Reports+Preliminary+First+Quarter+/26409359.html Thu, 30 Apr 2026 16:43:00 -0400 A.03854270 A.06372891 A.07275829 A.08164575 A.08377063 A.08423586 A.11399736 A.11608963 A.14067231 A.16852497 A.20009571 A.22499170 A.32289834 A.33634610 A.33902756 A.35454529 A.50203584 ANIK AXGN BVS ELUT MDXG O.00026248 O.00028494 O.00092737 O.00173818 O.01163638 O.02760651 O.04701423 O.04848105 O.05010326 O.05016941 O.06574964 O.07126568 O.08234601 O.15817314 O.18720149 O.19903583 O.20976440 O.24070172 O.25928637 O.29996804 O.30836334 O.31701438 O.59913331 TELA